CN114901688A - 针对念珠菌的抗体及其用途 - Google Patents

针对念珠菌的抗体及其用途 Download PDF

Info

Publication number
CN114901688A
CN114901688A CN202080068146.3A CN202080068146A CN114901688A CN 114901688 A CN114901688 A CN 114901688A CN 202080068146 A CN202080068146 A CN 202080068146A CN 114901688 A CN114901688 A CN 114901688A
Authority
CN
China
Prior art keywords
antibody
sequences
fragment
chain variable
clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080068146.3A
Other languages
English (en)
Chinese (zh)
Inventor
拉塞尔·B·威尔逊
辛洪
詹姆斯·E·鲁宾逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stadius Biopharmaceutical LLC
Tulane University
Louisiana State University
Original Assignee
Stadius Biopharmaceutical LLC
Tulane University
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stadius Biopharmaceutical LLC, Tulane University, Louisiana State University filed Critical Stadius Biopharmaceutical LLC
Publication of CN114901688A publication Critical patent/CN114901688A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080068146.3A 2019-07-29 2020-07-28 针对念珠菌的抗体及其用途 Pending CN114901688A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962879894P 2019-07-29 2019-07-29
US201962879912P 2019-07-29 2019-07-29
US62/879,894 2019-07-29
US62/879,912 2019-07-29
PCT/US2020/043908 WO2021021830A1 (en) 2019-07-29 2020-07-28 Antibodies to candida and uses thereof

Publications (1)

Publication Number Publication Date
CN114901688A true CN114901688A (zh) 2022-08-12

Family

ID=74230808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080068146.3A Pending CN114901688A (zh) 2019-07-29 2020-07-28 针对念珠菌的抗体及其用途

Country Status (8)

Country Link
US (1) US20220280618A1 (https=)
EP (1) EP4007772A4 (https=)
JP (1) JP7667773B2 (https=)
KR (1) KR102822827B1 (https=)
CN (1) CN114901688A (https=)
AU (1) AU2020323925A1 (https=)
CA (1) CA3146123A1 (https=)
WO (1) WO2021021830A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991752A (zh) * 2022-12-07 2023-04-21 中国科学技术大学 特定组氨酸甲基化修饰的pra1蛋白免疫原、多克隆抗体及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090760A1 (en) * 2023-10-25 2025-05-01 Board Of Regents, The University Of Texas System Antibodies specific to scube3 and methods of use
CN119930808B (zh) * 2025-01-09 2025-11-25 普健生物（武汉）科技有限公司 一种抗白念珠菌Csa2蛋白的单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203532A (zh) * 2005-03-18 2008-06-18 杜门蒂斯有限公司 抗念珠菌抗原的抗体
US20110189183A1 (en) * 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
CN107614517A (zh) * 2015-04-01 2018-01-19 台北医学大学 抗感染疾病的抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2651575B2 (ja) * 1987-07-13 1997-09-10 神鋼電機株式会社 インバータの過電流検出装置
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
EP2102244A2 (en) * 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2699257A4 (en) 2011-04-21 2014-10-15 Univ Louisiana State PEPTIDE AND CONJUGATE VACCINES FOR FUNGI INFECTIONS
US10590178B2 (en) 2014-06-25 2020-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chimeric vaccine against fungal infections
CN108368172B (zh) * 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203532A (zh) * 2005-03-18 2008-06-18 杜门蒂斯有限公司 抗念珠菌抗原的抗体
US20110189183A1 (en) * 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
CN107614517A (zh) * 2015-04-01 2018-01-19 台北医学大学 抗感染疾病的抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991752A (zh) * 2022-12-07 2023-04-21 中国科学技术大学 特定组氨酸甲基化修饰的pra1蛋白免疫原、多克隆抗体及应用
CN115991752B (zh) * 2022-12-07 2025-10-31 中国科学技术大学 特定组氨酸甲基化修饰的pra1蛋白免疫原、多克隆抗体及应用

Also Published As

Publication number Publication date
AU2020323925A1 (en) 2022-03-17
KR20220113346A (ko) 2022-08-12
JP2022542699A (ja) 2022-10-06
KR102822827B1 (ko) 2025-06-19
US20220280618A1 (en) 2022-09-08
EP4007772A4 (en) 2023-11-29
CA3146123A1 (en) 2021-02-04
EP4007772A1 (en) 2022-06-08
JP7667773B2 (ja) 2025-04-23
WO2021021830A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
JP7644087B2 (ja) エンテロウイルスｄ６８に対するヒトモノクローナル抗体
JP2023519105A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
JP7627687B2 (ja) Ｌｉｌｒｂ２に対するシングルドメイン抗体
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195485A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
JP7667773B2 (ja) カンジダ属に対する抗体およびその使用法
US20230063625A1 (en) Human antibodies to rift valley fever virus
US20230065377A1 (en) Human antibodies to alphaviruses
EP4259180A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
KR20120113580A (ko) 비브리오 패혈증균 알티엑스에이원에 특이적인 단일클론항체, 이를 분비하는 하이브리도마 및 이를 포함하는 진단키트
US20250145691A1 (en) Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
US20240085427A1 (en) AN AGR2Xcd3 BISPECIFIC ENGAGER FOR THE TREATMENT OF CANCER
CN115135345A (zh) 中和寨卡病毒的人抗体及其使用方法
CN121729618A (zh) 针对乙型流感病毒的广泛反应性抗体
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
US20240288426A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
CN116529259A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2023235666A2 (en) Human antibodies to bordetella pertussis and uses therefor
TW201400501A (zh) 新穎抗體及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220812

RJ01 Rejection of invention patent application after publication